WallStreetZenWallStreetZen

NASDAQ: PCVX
Vaxcyte Inc Stock

$106.67+3.97 (+3.87%)
Updated Nov 8, 2024
PCVX Price
$106.67
Fair Value Price
$3.79
Market Cap
$13.29B
52 Week Low
$46.16
52 Week High
$121.06
P/E
-23.19x
P/B
3.89x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$507.65M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.04
Operating Cash Flow
-$470M
Beta
0.8
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A

PCVX Overview

Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company also develops VAX-XP to protect against emerging strains and address antibiotic resistance; VAX-A1, a conjugate vaccine candidate designed to treat Group A Strep; and VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.

Zen Score

Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how PCVX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

PCVX ($106.67) is overvalued by 2,714.52% relative to our estimate of its Fair Value price of $3.79 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
PCVX ($106.67) is not significantly undervalued (2,714.52%) relative to our estimate of its Fair Value price of $3.79 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
PCVX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more PCVX due diligence checks available for Premium users.

Be the first to know about important PCVX news, forecast changes, insider trades & much more!

PCVX News

Valuation

PCVX fair value

Fair Value of PCVX stock based on Discounted Cash Flow (DCF)
Price
$106.67
Fair Value
$3.79
Overvalued by
2,714.52%
PCVX ($106.67) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
PCVX ($106.67) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
PCVX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

PCVX price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-23.19x
Industry
-131.49x
Market
25.76x

PCVX price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
3.89x
Industry
5.81x
PCVX is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

PCVX's financial health

Profit margin

Revenue
$0.0
Net Income
-$103.1M
Profit Margin
0%
PCVX's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials

Assets to liabilities

Assets
$3.6B
Liabilities
$142.1M
Debt to equity
0.04
PCVX's short-term assets ($2.21B) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
PCVX's short-term assets ($2.21B) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
PCVX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$60.7M
Investing
-$917.0M
Financing
$1.5B
PCVX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

PCVX vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
PCVX$13.29B+3.87%-23.19x3.89x
INSM$13.16B+2.58%-13.25x27.22x
BMRN$12.78B+0.19%39.45x2.36x
TECH$12.07B-0.60%79.96x5.64x
SRPT$11.62B+0.99%77.96x9.51x

Vaxcyte Stock FAQ

What is Vaxcyte's quote symbol?

(NASDAQ: PCVX) Vaxcyte trades on the NASDAQ under the ticker symbol PCVX. Vaxcyte stock quotes can also be displayed as NASDAQ: PCVX.

If you're new to stock investing, here's how to buy Vaxcyte stock.

What is the 52 week high and low for Vaxcyte (NASDAQ: PCVX)?

(NASDAQ: PCVX) Vaxcyte's 52-week high was $121.06, and its 52-week low was $46.16. It is currently -11.88% from its 52-week high and 131.09% from its 52-week low.

How much is Vaxcyte stock worth today?

(NASDAQ: PCVX) Vaxcyte currently has 124,636,546 outstanding shares. With Vaxcyte stock trading at $106.67 per share, the total value of Vaxcyte stock (market capitalization) is $13.29B.

Vaxcyte stock was originally listed at a price of $26.15 in Jun 12, 2020. If you had invested in Vaxcyte stock at $26.15, your return over the last 4 years would have been 307.92%, for an annualized return of 42.12% (not including any dividends or dividend reinvestments).

How much is Vaxcyte's stock price per share?

(NASDAQ: PCVX) Vaxcyte stock price per share is $106.67 today (as of Nov 8, 2024).

What is Vaxcyte's Market Cap?

(NASDAQ: PCVX) Vaxcyte's market cap is $13.29B, as of Nov 11, 2024.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Vaxcyte's market cap is calculated by multiplying PCVX's current stock price of $106.67 by PCVX's total outstanding shares of 124,636,546.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.